首页> 外文期刊>Biomarker Research >Detection of Epstein-Barr virus (EBV) in human lymphoma tissue by a novel microbial detection array
【24h】

Detection of Epstein-Barr virus (EBV) in human lymphoma tissue by a novel microbial detection array

机译:新型微生物检测阵列检测人淋巴瘤组织中的爱泼斯坦-巴尔病毒(EBV)

获取原文
           

摘要

BackgroundInfectious agents are estimated to play a causative role in approximately 20% of cancers worldwide. Viruses, notably the Epstein-Barr virus (EBV), are associated with 10-15% of B-cell lymphomas and are found at a higher frequency in immunosuppressed patients. In this study, we screened human lymphoma tissues using a novel Lawrence Livermore Microbial Detection Array (LLMDA), a comprehensive detection system that contains probes for all sequenced viruses and bacteria. This technology has been applied to identify pathogen-associated diseases. ResultsWe evaluated samples from 58 cases with various lymphoid tissue disorders using LLMDA. These included 30 B-cell lymphomas (9 indolent and 21 aggressive type), 2?T-cell lymphomas and 2 NK/T cell lymphomas, 4 plasmacytomas as well as 8 specimens of benign lymphoid tissue. Five of 21 high-grade B-cell lymphomas were positive for Epstein-Barr virus-encoded small RNA (EBER+), while all the indolent B-cell lymphomas were EBER-. Similarly, both NK/T cell lymphomas were EBER+, and the benign tissues were EBER-. We also screened 10 cases of post-transplant lymphoproliferative disorder (PTLD). Five of these cases (4 B-cell lymphomas and 1 NK/T cell lymphoma) were EBER+, and the remaining five cases were EBER-. ConclusionsWe have confirmed the reliability of the LLMDA methods by detecting EBV in EBV-positive lymphomas while observing no false-positive results in EBV-negative lymphomas. The LLMDA technique provides a sensitive and alternative method for identifying known viral pathogen associated with tumors and may prove useful for future clinical identification of novel cancer-associated viral pathogens.
机译:背景技术据估计,传染病在全世界约20%的癌症中起着致病作用。病毒,特别是爱泼斯坦-巴尔病毒(EBV),与10-15%的B细胞淋巴瘤相关,在免疫抑制的患者中发现的频率更高。在这项研究中,我们使用新型的劳伦斯·利弗莫尔微生物检测阵列(LLMDA)筛选了人类淋巴瘤组织,这是一个全面的检测系统,其中包含所有已测序病毒和细菌的探针。该技术已被应用于识别病原体相关疾病。结果我们使用LLMDA评估了58例各种淋巴组织疾病患者的样本。其中包括30例B细胞淋巴瘤(9例惰性和21例侵袭性),2例T细胞淋巴瘤和2例NK / T细胞淋巴瘤,4例浆细胞瘤以及8例良性淋巴组织标本。 21例高级B细胞淋巴瘤中有5例经爱泼斯坦-巴尔病毒编码的小RNA(EBER +)阳性,而所有惰性B细胞淋巴瘤均为EBER-。同样,两种NK / T细胞淋巴瘤均为EBER +,良性组织为EBER-。我们还筛选了10例移植后淋巴细胞增生性疾病(PTLD)。其中5例(4例B细胞淋巴瘤和1例NK / T细胞淋巴瘤)为EBER +,其余5例为EBER-。结论我们已经通过检测EBV阳性淋巴瘤中的EBV证实了LLMDA方法的可靠性,同时未观察到EBV阴性淋巴瘤的假阳性结果。 LLMDA技术为鉴定与肿瘤相关的已知病毒病原体提供了一种灵敏的替代方法,并且可能被证明可用于未来与新型癌症相关的病毒病原体的临床鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号